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HOW TO DEAL WITH DECISION UNCERTAINTY? THE ITALIAN EXPERIENCE
WITH MANAGED ENTRY AGREEMENTS
Siviero PD, Sammarco A, Tafuri G, Pani L
Italian Medicines Agency, Rome, Italy
OBJECTIVES: To ensure rapid access to new potentially beneficial medicines and
affordability, payers are adopting innovative approaches called Managed Entry
Agreement(MEAs). AIFA has pioneered in the design and implementation of MEAs
for the last two decades. The objective is to describe and quantify AIFA’sMEAs used
to support decision-making in situations of uncertainty.METHODS: Data on MEAs
were retrieved from the AIFA monitoring registries and databases, and analyzed
between August 1st 2011 and December 15th 2011. RESULTS: The management of
uncertainty of new medicines/therapeutic indications(TI) is performed through
arrangements based on access with evidence development i.e. “AIFA monitoring
registries” which can be associated with outcome based schemes: “Payment by
Results(PbR)” or “Risk-Sharing(RS)”. To manage utilization, AIFA set “Restricting
Notes for Prescription”(RNP), a tool to restrict NHS reimbursability of medicines for
a particular condition/disease, and the “Therapeutic Plans”(TP), which guarantee
reimbursement only under specialist monitoring. To achievemanagement of bud-
get impact, financial-oriented schemes are in place: The “Volume-based Agree-
ments”(VbA), a negotiation of volume of sales between AIFA and manufacturers,
and the Cost-sharing(CS), a discount on the initial therapy cycle(s) for all eligible
patients. The AIFA Registries include 78 TI: 44 refer to oncology, 15 to rare diseases,
7 to diabetes and the remaining to other therapeutic areas. Among 78 TI, 14 were
PbR, 12 CS and 2 RS. For the remaining 50 indications, no scheme for reimburse-
ment was applied, but registries were used to monitor post-marketing safety and
effectiveness. Furthermore AIFA implemented 32 RNP and a total of 85 VbA and TP
for more than 350 medicines. CONCLUSIONS: Unlike other European authorities
which base reimbursement decisions on thresholds, AIFA implemented an exten-
sive range of strategies to allowhealth care access and budget sustainability. These
strategies ensure proper utilization of standard therapies and guarantee access to
most recent innovative medicines.
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DEFINING ELEMENTS OF VALUE FOR RARE DISEASE TREATMENTS
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Rare diseases are an important medical and social issue. Although the prevalence
of individual diseases is by definition low, in aggregate the number of people af-
fected by a rare disease is considerable. These conditions are characterized by
severe, debilitating symptoms that substantially affect life expectancy, physical
and social functioning, and quality of life of patients and their families. The ques-
tion of what constitutes value for rare disease drugs, and how this should be eval-
uated, is central to the successful continuation of the orphan drug market, and to
properly support asset value-based pricing. The objective of this work was to pro-
vide preliminary insight into the elements of value which are important when
assessing rare disease treatments and how they might be considered together
within a value framework. A literature review sought to identify elements of value
that are currently considered by European payers when assessing rare disease
treatments, those described in patient group surveys, and value elements that
have been quantified and described empirically for existing drugs. A generic con-
ceptual value framework was derived based upon the literature review, and this
was tested with rare disease experts, patient group representatives, and payers.
Multiple criteria are considered in assessing the value of rare diseases treatments,
including burden of disease, therapeutic benefit, familial and societal impact, and
economic and budgetary implications. Scientific innovation was also considered,
but primarily as a supporting rationale for therapeutic benefit. Clinical/social out-
come anchored evidence and data uncertainty were seen to be key factors in de-
termining perceived value. In future, payers will need to develop assessment
frameworks that better reflect the societal value of treatments for rare diseases.
This value is perceived throughmultiple domains that are not always incorporated
in current payer mechanisms. Multi-criteria decision analysis offers a possible
construct for incorporating these elements in future.
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LEGAL IMPACT OF PHARMACEUTICAL PRICING IN THE GERMAN STATUTORY
HEALTH INSURANCE SYSTEM
Gissel C
Justus Liebig University Giessen, Giessen, Hessen, Germany
OBJECTIVES: After the failure of the efficiency frontier approach, Germany intro-
duced rebate negotiations for all new drugs in the Statutory Health Insurance
system in 2011. We aim to compare the legal impact of both approaches on consti-
tutional rights. METHODS: We apply a legal analysis with regard to the constitu-
tional rights affected by both approaches. RESULTS: In the new system of negoti-
ating prices, manufacturers are free to negotiate any rebate. However, if the
negotiations do not result in an agreement, an arbitration board determines the
rebate. Themanufacturer cannot directly influence the board’s decision. The board
considers both the drug’s benefit compared to existing drugs and the European
price level as a reference. The board’s decision is binding until a new agreement
has been negotiated. With the efficiency frontier approach, the Statutory Health
Insurance funds set a maximum reimbursable price based on cost-effectiveness
analysis with the efficiency frontier. The manufacturer remains free to charge any
price, resulting in patients’ out-of-pocket payments. In the negotiations system,
the manufacturers lose their economic freedom to exercise the right to offer their
product at any price. In the efficiency frontier system, access to drugs is effectively
rationed for patients despite their membership in the Statutory Health Insurance.
Their constitutional right to life and health is affected. CONCLUSIONS: Assuming
that there is always a difference between the price amanufacturer wants to charge
and the price the Statutory Health Insurance funds want to pay, the legislator
needs to decide who has to cover the economic burden. The legislator faces a
trade-off between manufacturers’ and patients’ constitutional rights. In the Ger-
man constitution, the right to life and health is more important than economic
freedom.
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FROM VALUE TO PRICE: WHAT SHOULD BE THE PATH FOR ORPHAN DRUGS?
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Setting an appropriate price for an innovative orphan drug is increasingly difficult
in today’s resource constrained health care systems.What constitutes the value of
orphan drugs is mainly perceived as empirical and a function of their rarity. The
conventional cost-effectiveness (CE) approach analysis implies the use of a CE
threshold. The determination of this threshold for orphan drugs is a contrived
exercise and can make the pricing decision hard to justify in the eyes of many
stakeholders, notably clinicians and patients. In this conceptual research, we ex-
plore the use of a value-based pricingmathematical function to link the incremen-
tal value brought by innovative orphan drugs to their prices. This function depicts
the incremental value-based price (Y-axis) against the incremental value (X-axis).
Value is holistically considered and embraces multiple clinical, humanistic and
societal criteria that can be weighted by stakeholders (clinicians, patients, caregiv-
ers and payers). The incremental value is thus assessed throughout multi-criteria
decision analysis (MCDA) and is finally embodied into a unified value score. The
value-based price is expressed as a function of this value score. The exact shape of
this value-based pricing function is obviously unknown. However, we stipulate
that it has to satisfy two necessary conditions:) growing, and 2) bounded by the
maximumwillingness-to-pay (WTP) for the ultimate achievable incremental value
(e.g. cure of the disease).We compare two functional forms: linear and sigmoid and
we debatemultipleWTP scenarios and perspectives. Finally, we conclude that this
simple and transparent mathematical approach might prove useful to inform val-
ue-based pricing. When combined with MCDA, the approach makes more explicit
the relevant value determinants and incorporates these determinants in a more
holistic value and pricing framework for rare disease treatments. Empirical works,
however, are needed to further substantiate the approach in the eyes of decision
makers.
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Double Helix Consulting Group, London, UK
OBJECTIVES: The importance given to different domains of decisions differ by
markets around the world. The research is aimed to analyse how perspectives on
value assessment of pharmaceuticals or device interventions vary across markets
and how it is likely to be implemented in the United Kingdom. The research also
analysed how products at launch increase the chances of approval, shorten time to
reimbursement and remain competitive within the value based pricing agenda.
METHODS: The research was conducted through indepth secondary research and
interviews with stakeholders in the United Kingdom and selected markets (Aus-
tralia, Sweden and The Netherlands) RESULTS: The research indicated that most
countries, other than those that use international price referencing for setting
prices use some formof value assessmentmethod before fixing the reimbursement
level and price of the product. The decisions are predominantly based on level of
unmet needs, severity of diseases, level of innovation, clinical differentiation of the
new product against its comparators and how well the product finds it natural
place in the treatment pathway. Many forward regions claim to use value based
assessments to set the price of new launches, most operate within boundaries. In
principal value based pricing should not be fenced with limitations such as cost/
QaLY thresholds, budget impact and price-volume agreements. In real life, how-
ever, financial impact becomes one of the key influencing factors and is expected to
dominate in the near future too. CONCLUSIONS: It is difficult to assess the true
value of a product at launch and it is difficult for both, the health authorities who
have limited budgets and pharmaceutical industry which spends enormous
amounts to bring products to market. VBP, however, could be the most suitable
solution for the UK. If successful international markets may adopt it or refer to UK
recommendations on new launches for their respective decisions.
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POTENTIAL IMPLICATIONS OF NATIONAL DISEASE REGISTRIES AND CENTERS
OF EXCELLENCE FOR ORPHAN DISEASES FOR PHARMACEUTICAL
MANUFACTURERS DEVELOPING ORPHAN DRUGS
Dobrovolny D, Patel A, Dalsania R, Paas M
Bridgehead International Ltd, New York, NY, USA
BACKGROUND: Recent recommendations from the EU commission have given
countries the responsibility to develop national strategies for rare diseases, includ-
ing plans for inventorying of rare diseases and development of centers of excel-
lence (CoE). In France, patients are required to consult or obtain their prescription
from a CoE in order for reimbursement of orphan drugs to be granted. As CoE and
rare disease registries are developed throughout the EU member states, increased
awareness, education, and data collection will lead to better management of or-
phan diseases, monitoring of long-term outcomes and cost and opportunities for
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